Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis

References

• McDowell PJ, Heaney LG. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020;75:302–310. doi:10.1111/all.13966
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Severe adult asthmas: integrating clinical features, biology and therapeutics to improve outcomes. Am J Respir Crit Care Med. 2021;203:809–821. doi:10.1164/rccm.202009-3631CI
   PubMed Web of Science ®Google Scholar
• Camiolo MJ, Kale SL, Oriss TB, et al. Immune responses and exacerbations in severe asthma. Curr Opin Immunol. 2021;72:34–42. doi:10.1016/j.coi.2021.03.004
   Web of Science ®Google Scholar
• Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197:22–37. doi:10.1164/rccm.201611-2232PP
   PubMed Web of Science ®Google Scholar
• Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184:1469–1485. doi:10.1016/j.cell.2021.02.016
   PubMed Web of Science ®Google Scholar
• Matucci A, Bormioli S, Nencini F, et al. The emerging role of type 2 inflammation in asthma. Expert Rev Clin Immunol. 2021;17:63–71. doi:10.1080/1744666X.2020.1860755
   PubMed Web of Science ®Google Scholar
• Tran TN, Zeiger RS, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116:37–42. doi:10.1016/j.anai.2015.10.027
   PubMed Web of Science ®Google Scholar
• Nelson RK, Bush A, Stokes J, et al. Eosinophilic asthma. J Allergy Clin Immunol Pract. 2020;8:465–473. doi:10.1016/j.jaip.2019.11.024
   PubMed Web of Science ®Google Scholar
• Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR). Respir Med. 2014;108:1723–1732. doi:10.1016/j.rmed.2014.10.007
   PubMed Web of Science ®Google Scholar
• Rossios C, Pavlidis S, Hoda U, et al. Unbiased biomarkers for the prediction of respiratory diseases outcomes (U-BIOPRED) consortia project team. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. J Allergy Clin Immunol. 2018;141:560–570. doi:10.1016/j.jaci.2017.02.045
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56:219–233. doi:10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rodriguez N, Gogoi M, McKenzie ANJ. Group 2 innate lymphoid cells: team players in regulating asthma. Annu Rev Immunol. 2021;39:167–198. doi:10.1146/annurev-immunol-110119-091711
   Web of Science ®Google Scholar
• Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest. 2019;129:1441–1451. doi:10.1172/JCI124606
   PubMed Web of Science ®Google Scholar
• Maggi L, Montaini G, Mazzoni A, et al. Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production. J Allergy Clin Immunol. 2017;139:964–976. doi:10.1016/j.jaci.2016.06.032
   PubMed Web of Science ®Google Scholar
• Froidure A, Mouthuy J, Durham SR, et al. Asthma phenotypes and IgE responses. Eur Respir J. 2016;47:304–319. doi:10.1183/13993003.01824-2014
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50:975–991. doi:10.1016/j.immuni.2019.03.018
   PubMed Web of Science ®Google Scholar
• Gour N, Wills-Karp M. IL-4 and IL-13 in allergic airway disease. Cytokine. 2015;75:68–78. doi:10.1016/j.cyto.2015.05.014
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Silkoff PE. Perspectives on exhaled nitric oxide. J Breath Res. 2017;11:047104. doi:10.1088/1752-7163/aa7f0e
   Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Vatrella A, et al. Molecular targets for biological therapies of severe asthma. Front Immunol. 2020;11:603312. doi:10.3389/fimmu.2020.603312
   PubMed Web of Science ®Google Scholar
• Pelaia C, Pelaia G, Crimi C, et al. Biologics in severe asthma. Minerva Med. 2021.
   Web of Science ®Google Scholar
• Suraya R, Nagano T, Katsurada M, et al. Molecular mechanism of asthma and its novel molecular target therapeutic agent. Respir Investig. 2021;59(3):291–301. doi:10.1016/j.resinv.2020.12.007
   Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Gallelli L, et al. Dupilumab for the treatment of asthma. Expert Opin Biol Ther. 2017;17:1565–1572. doi:10.1080/14712598.2017.1387245
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila T. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50:5–14. doi:10.1111/cea.13491
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650. doi:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag. 2020;16:31–37. doi:10.2147/TCRM.S210648
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757–1769. doi:10.2147/DDDT.S243053
   PubMed Web of Science ®Google Scholar
• Nettis E, Patella V, Lombardo C, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. Allergy. 2020;10:2653–2661. doi:10.1111/all.14338
   Web of Science ®Google Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50:789–798. doi:10.1111/cea.13614
   PubMed Web of Science ®Google Scholar
• Campisi R, Crimi C, Nolasco S, et al. Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program. J Asthma Allergy. 2021;14:575–583. doi:10.2147/JAA.S312123
   PubMed Web of Science ®Google Scholar
• Bakker DS, van der Wal MM, Heeb LEM, et al. Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis. J Invest Dermatol. 2021;141:1943–1953. doi:10.1016/j.jid.2021.01.022
   Web of Science ®Google Scholar
• Malling HJ. Skin prick testing and the use of histamine references. Allergy. 1984;39:596–601. doi:10.1111/j.1398-9995.1984.tb01979.x
   PubMed Web of Science ®Google Scholar
• Laufer P, Chryssanthopoulos C, Laufer R, Hause LL. The determination of the eosinophil count: comparison of two techniques. J Allergy Clin Immunol. 1987;79:438–441. doi:10.1016/0091-6749(87)90360-5
   Web of Science ®Google Scholar
• Borzova E, Dahinden CA. The absolute basophil count. Methods Mol Biol. 2014;1192:87–100.
   PubMedGoogle Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12. doi:10.4193/Rhino50E2
   PubMed Web of Science ®Google Scholar
• Lombardo N, Pelaia C, Ciriolo M, et al. Real-life of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851. doi:10.1177/2058738420950851
   Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44. doi:10.1016/S0140-6736(16)30307-5
   PubMed Web of Science ®Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70–e88. doi:10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–930. doi:10.1164/rccm.200406-710ST
   PubMed Web of Science ®Google Scholar
• Horváth I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49:1600965. doi:10.1183/13993003.00965-2016
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65. doi:10.1016/j.jaci.2003.09.008
   PubMed Web of Science ®Google Scholar
• Jia CE, Zhang HP, Lv Y, et al. The asthma control test and the asthma control questionnaire for assessing asthma control: systematic review and meta-analysis. J Allergy Clin Immunol. 2013;131:695–703. doi:10.1016/j.jaci.2012.08.023
   PubMed Web of Science ®Google Scholar
• Heffler E, Blasi F, Latorre M, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7:1462–1468. doi:10.1016/j.jaip.2018.10.016
   PubMed Web of Science ®Google Scholar
• Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the severe asthma network in Italy (SANI) registry. World Allergy Organ J. 2019;12:100007. doi:10.1016/j.waojou.2018.12.001
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020;75:148–157. doi:10.1111/all.13984
   PubMed Web of Science ®Google Scholar
• Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma – lessons learned from the National Heart, Lung and Blood Institute severe asthma research program. Am J Respir Crit Care Med. 2012;185:356–362. doi:10.1164/rccm.201107-1317PP
   PubMed Web of Science ®Google Scholar
• Carr TF, Kraft M. Use of biomarkers to identify phenotypes and endotypes of severe asthma. Ann Allergy Asthma Immunol. 2018;121:414–420. doi:10.1016/j.anai.2018.07.029
   PubMed Web of Science ®Google Scholar
• Busse WW, Kraft M, Rabe KF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;4:2003393. doi:10.1183/13993003.03393-2020
   Web of Science ®Google Scholar
• Ulrik CS, Lange P, Hilberg O. Fractional exhaled nitric oxide as a determinant for the clinical course of asthma: a systematic review. Eur Clin Respir J. 2021;8:1891725. doi:10.1080/20018525.2021.1891725
   Web of Science ®Google Scholar
• Rolla G, Heffler E, Pizzimenti S. An emerging role for exhaled nitric oxide in guiding biological treatment in severe asthma. Curr Med Chem. 2020;27:7159–7167. doi:10.2174/0929867327666200713184659
   Web of Science ®Google Scholar
• Scadding GK, Scadding GW. Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases. J Allergy Clin Immunol Pract. 2021;9:1851–1857. doi:10.1016/j.jaip.2021.02.013
   Web of Science ®Google Scholar
• Matucci A, Bormioli S, Nencini F, et al. Asthma and chronic rhinosinusitis: how similar are they in pathogenesis and treatment responses? Int J Mol Sci. 2021;22:3340. doi:10.3390/ijms22073340z
   PubMed Web of Science ®Google Scholar